Linked Life Data

2937503

Source:http://linkedlifedata.com/resource/pubmed/id/2937503

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2937503rdf:typepubmed:Citationlld:pubmed
pubmed-article:2937503lifeskim:mentionsumls-concept:C0007450lld:lifeskim
pubmed-article:2937503lifeskim:mentionsumls-concept:C0039231lld:lifeskim
pubmed-article:2937503lifeskim:mentionsumls-concept:C0042401lld:lifeskim
pubmed-article:2937503lifeskim:mentionsumls-concept:C0243192lld:lifeskim
pubmed-article:2937503lifeskim:mentionsumls-concept:C0034838lld:lifeskim
pubmed-article:2937503lifeskim:mentionsumls-concept:C0086597lld:lifeskim
pubmed-article:2937503lifeskim:mentionsumls-concept:C0049095lld:lifeskim
pubmed-article:2937503pubmed:issue2lld:pubmed
pubmed-article:2937503pubmed:dateCreated1986-5-1lld:pubmed
pubmed-article:2937503pubmed:abstractTextWe have attempted to characterize the 5-hydroxytryptamine (5-HT) receptors mediating bronchoconstriction, vasodilatation, vasodepression and tachycardia in anaesthetized cats following bilateral vagosympathectomy and beta-adrenoceptor blockade with propranolol. 5-HT (1-100 micrograms/kg-1 i.v.) caused dose-related bronchoconstriction and tachycardia but variable and complex effects on diastolic blood pressure and carotid arterial vascular resistance. In contrast, 5-carboxamidotryptamine (5-CT; 0.01-1 micrograms kg-1 i.v.) caused consistent, dose-related decreases in diastolic blood pressure and carotid arterial vascular resistance and increases in heart rate. 5-CT did not cause bronchoconstriction. The 5-HT-induced bronchoconstriction was dose-dependently antagonized by methiothepin, methysergide and ketanserin (10-100 micrograms kg-1 i.v.). The highest doses used of these antagonists did not antagonize bronchoconstriction induced by prostaglandin F2 alpha. The high potency of all three antagonists indicate a 5-HT2-receptor mediated effect. The 5-HT- and 5-CT-induced tachycardia as well as the 5-CT-induced vasodepressor and carotid arterial vasodilator responses were dose-dependently antagonized by low doses of methiothepin (10-100 micrograms kg-1 i.v.) and by high doses of methysergide (100-1000 micrograms kg-1 i.v.) but were little affected by ketanserin in doses up to 1000 micrograms kg-1 i.v. These selective effects of 5-CT appear to be mediated by '5-HT1-like' receptors.lld:pubmed
pubmed-article:2937503pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:languageenglld:pubmed
pubmed-article:2937503pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:citationSubsetIMlld:pubmed
pubmed-article:2937503pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2937503pubmed:statusMEDLINElld:pubmed
pubmed-article:2937503pubmed:monthFeblld:pubmed
pubmed-article:2937503pubmed:issn0007-1188lld:pubmed
pubmed-article:2937503pubmed:authorpubmed-author:HumphreyP PPPlld:pubmed
pubmed-article:2937503pubmed:authorpubmed-author:FeniukWWlld:pubmed
pubmed-article:2937503pubmed:authorpubmed-author:ConnorH EHElld:pubmed
pubmed-article:2937503pubmed:authorpubmed-author:PerrenM JMJlld:pubmed
pubmed-article:2937503pubmed:issnTypePrintlld:pubmed
pubmed-article:2937503pubmed:volume87lld:pubmed
pubmed-article:2937503pubmed:ownerNLMlld:pubmed
pubmed-article:2937503pubmed:authorsCompleteYlld:pubmed
pubmed-article:2937503pubmed:pagination417-26lld:pubmed
pubmed-article:2937503pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:2937503pubmed:meshHeadingpubmed-meshheading:2937503-...lld:pubmed
pubmed-article:2937503pubmed:meshHeadingpubmed-meshheading:2937503-...lld:pubmed
pubmed-article:2937503pubmed:meshHeadingpubmed-meshheading:2937503-...lld:pubmed
pubmed-article:2937503pubmed:meshHeadingpubmed-meshheading:2937503-...lld:pubmed
pubmed-article:2937503pubmed:meshHeadingpubmed-meshheading:2937503-...lld:pubmed
pubmed-article:2937503pubmed:meshHeadingpubmed-meshheading:2937503-...lld:pubmed
pubmed-article:2937503pubmed:meshHeadingpubmed-meshheading:2937503-...lld:pubmed
pubmed-article:2937503pubmed:meshHeadingpubmed-meshheading:2937503-...lld:pubmed
pubmed-article:2937503pubmed:meshHeadingpubmed-meshheading:2937503-...lld:pubmed
pubmed-article:2937503pubmed:meshHeadingpubmed-meshheading:2937503-...lld:pubmed
pubmed-article:2937503pubmed:meshHeadingpubmed-meshheading:2937503-...lld:pubmed
pubmed-article:2937503pubmed:meshHeadingpubmed-meshheading:2937503-...lld:pubmed
pubmed-article:2937503pubmed:meshHeadingpubmed-meshheading:2937503-...lld:pubmed
pubmed-article:2937503pubmed:meshHeadingpubmed-meshheading:2937503-...lld:pubmed
pubmed-article:2937503pubmed:meshHeadingpubmed-meshheading:2937503-...lld:pubmed
pubmed-article:2937503pubmed:year1986lld:pubmed
pubmed-article:2937503pubmed:articleTitle5-Carboxamidotryptamine is a selective agonist at 5-hydroxytryptamine receptors mediating vasodilatation and tachycardia in anaesthetized cats.lld:pubmed
pubmed-article:2937503pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2937503lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2937503lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2937503lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2937503lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2937503lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2937503lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2937503lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2937503lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2937503lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2937503lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2937503lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2937503lld:pubmed